Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
2000 1
2002 2
2003 3
2009 2
2011 1
2012 2
2013 3
2014 1
2015 4
2016 3
2017 5
2018 2
2019 4
2020 5
2021 10
2022 7
2023 4

Text availability

Article attribute

Article type

Publication date

Search Results

51 results

Results by year

Filters applied: . Clear all
Page 1
Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial.
Gnant M, Pfeiler G, Dubsky PC, Hubalek M, Greil R, Jakesz R, Wette V, Balic M, Haslbauer F, Melbinger E, Bjelic-Radisic V, Artner-Matuschek S, Fitzal F, Marth C, Sevelda P, Mlineritsch B, Steger GG, Manfreda D, Exner R, Egle D, Bergh J, Kainberger F, Talbot S, Warner D, Fesl C, Singer CF; Austrian Breast and Colorectal Cancer Study Group. Gnant M, et al. Among authors: exner r. Lancet. 2015 Aug 1;386(9992):433-43. doi: 10.1016/S0140-6736(15)60995-3. Epub 2015 May 31. Lancet. 2015. PMID: 26040499 Clinical Trial.
Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Gnant M, Pfeiler G, Steger GG, Egle D, Greil R, Fitzal F, Wette V, Balic M, Haslbauer F, Melbinger-Zeinitzer E, Bjelic-Radisic V, Jakesz R, Marth C, Sevelda P, Mlineritsch B, Exner R, Fesl C, Frantal S, Singer CF; Austrian Breast and Colorectal Cancer Study Group. Gnant M, et al. Among authors: exner r. Lancet Oncol. 2019 Mar;20(3):339-351. doi: 10.1016/S1470-2045(18)30862-3. Epub 2019 Feb 19. Lancet Oncol. 2019. PMID: 30795951 Clinical Trial.
Adjuvant Bisphosphonates and Breast Cancer Survival.
Strobl S, Korkmaz B, Devyatko Y, Schuetz M, Exner R, Dubsky PC, Jakesz R, Gnant M. Strobl S, et al. Among authors: exner r. Annu Rev Med. 2016;67:1-10. doi: 10.1146/annurev-med-053014-103600. Epub 2015 Aug 28. Annu Rev Med. 2016. PMID: 26332000 Review.
Adjuvant Bisphosphonate Therapy in Postmenopausal Breast Cancer.
Strobl S, Wimmer K, Exner R, Devyatko Y, Bolliger M, Fitzal F, Gnant M. Strobl S, et al. Among authors: exner r. Curr Treat Options Oncol. 2018 Mar 12;19(4):18. doi: 10.1007/s11864-018-0535-z. Curr Treat Options Oncol. 2018. PMID: 29527635 Review.
Local therapies for breast cancer.
Exner R. Exner R. Memo. 2017;10(3):181-184. doi: 10.1007/s12254-017-0336-2. Epub 2017 Jun 7. Memo. 2017. PMID: 28989544 Free PMC article. Review.
Therapeutic potential of glutathione.
Exner R, Wessner B, Manhart N, Roth E. Exner R, et al. Wien Klin Wochenschr. 2000 Jul 28;112(14):610-6. Wien Klin Wochenschr. 2000. PMID: 11008322 Review.
Optimal duration of adjuvant endocrine therapy: how to apply the newest data.
Wimmer K, Strobl S, Bolliger M, Devyatko Y, Korkmaz B, Exner R, Fitzal F, Gnant M. Wimmer K, et al. Among authors: exner r. Ther Adv Med Oncol. 2017 Nov;9(11):679-692. doi: 10.1177/1758834017732966. Epub 2017 Oct 27. Ther Adv Med Oncol. 2017. PMID: 29344105 Free PMC article. Review.
Rational design of an argon-binding superelectrophilic anion.
Mayer M, van Lessen V, Rohdenburg M, Hou GL, Yang Z, Exner RM, Aprà E, Azov VA, Grabowsky S, Xantheas SS, Asmis KR, Wang XB, Jenne C, Warneke J. Mayer M, et al. Among authors: exner rm. Proc Natl Acad Sci U S A. 2019 Apr 23;116(17):8167-8172. doi: 10.1073/pnas.1820812116. Epub 2019 Apr 5. Proc Natl Acad Sci U S A. 2019. PMID: 30952786 Free PMC article.
51 results